Tenax Therapeutics

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions.

The Company's development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.

Type
Public
HQ
Morrisville, US
Size (employees)
10 (est)
Tenax Therapeutics is headquartered in Morrisville, US

Tenax Therapeutics Office Locations

Tenax Therapeutics has an office in Morrisville
Morrisville, US (HQ)
490 1 Copley Pkwy

Tenax Therapeutics Data and Metrics

Tenax Therapeutics Financial Metrics

Tenax Therapeutics's revenue was reported to be $0 in FY, 2016 which is a 100% decrease from the previous period.
USD

Revenue growth (FY, 2015 - FY, 2016), %

(100%)

Net income (FY, 2016)

(43.9 m)

EBIT (FY, 2016)

(52.7 m)

Market capitalization (23-Jun-2017)

16.4 m

Closing share price (23-Jun-2017)

0.6

Cash (31-Dec-2016)

10 m

EV

6.4 m
Tenax Therapeutics's current market capitalization is $16.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

158.9 k49.3 k

Revenue growth, %

(69%)(100%)

Operating expense total

16.8 m14.9 m52.7 m

EBIT

(16.6 m)(14.8 m)(52.7 m)

EBIT margin, %

(10452%)(30063%)

Interest expense

2.2 m49.1 k

Net Income

(19.5 m)(14.1 m)(43.9 m)
USDFY, 2014FY, 2015FY, 2016

Cash

58.3 m7.9 m10 m

Accounts Receivable

36.4 k76.5 k72.6 k

Current Assets

59 m17.5 m13.6 m

PP&E

124.4 k50.3 k19.1 k

Goodwill

11.3 m11.3 m

Total Assets

93.4 m82.9 m23.3 m

Accounts Payable

411.1 k1.2 m727.6 k

Total Debt

346.9 k100.2 k

Current Liabilities

2.6 m4.5 m6.2 m

Additional Paid-in Capital

219.5 m221.1 m221.8 m

Retained Earnings

(136.6 m)(150.7 m)(204.7 m)

Total Equity

82.9 m70.4 m17.1 m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1.2 x1.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(19.5 m)(14.1 m)(43.9 m)

Depreciation and Amortization

150.5 k148.1 k19 k

Cash From Operating Activities

(9.3 m)(9.7 m)(15.9 m)

Purchases of PP&E

(9.8 k)(4.2 k)(2.9 k)

Cash From Investing Activities

(147 k)(40.9 m)22.2 m

Cash From Financing Activities

66.9 m280.6 k
Y, 2016

EV/EBIT

-0.1 x

EV/CFO

-0.4 x

Financial Leverage

1.4 x

Tenax Therapeutics Operating Metrics

FY, 2016

Phase III Trials

1

Patents Issued

7

Phase Preclinical

1

Tenax Therapeutics Market Value History

Tenax Therapeutics Company Life and Culture

You may also be interested in